Natera Inc (NTRA)

$102.67

+0.52

(+0.51%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $101.48
    $104.51
    $102.67
    downward going graph

    1.16%

    Downside

    Day's Volatility :2.9%

    Upside

    1.76%

    downward going graph
  • $36.90
    $117.23
    $102.67
    downward going graph

    64.06%

    Downside

    52 Weeks Volatility :68.52%

    Upside

    12.42%

    downward going graph

Returns

PeriodNatera IncSector (Health Care)Index (Russel 2000)
3 Months
11.44%
6.5%
0.0%
6 Months
56.1%
7.1%
0.0%
1 Year
116.79%
9.8%
0.0%
3 Years
-7.59%
14.2%
-20.2%

Highlights

Market Capitalization
12.8B
Book Value
$6.5
Earnings Per Share (EPS)
-3.11
PEG Ratio
0.0
Wall Street Target Price
125.39
Profit Margin
-30.24%
Operating Margin TTM
-20.21%
Return On Assets TTM
-17.14%
Return On Equity TTM
-50.59%
Revenue TTM
1.2B
Revenue Per Share TTM
10.31
Quarterly Revenue Growth YOY
52.1%
Gross Profit TTM
364.0M
EBITDA
-358.6M
Diluted Eps TTM
-3.11
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.44
EPS Estimate Next Year
-1.18
EPS Estimate Current Quarter
-0.7
EPS Estimate Next Quarter
-0.63

Analyst Recommendation

Buy
    91%Buy
    4%Hold
    4%Sell
Based on 23 Wall street analysts offering stock ratings for Natera Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
20
20
Hold
1
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 22.13%

Current $102.67
Target $125.39

Company Financials

FY18Y/Y Change
Revenue
257.7M
↑ 22.15%
Net Income
-128.2M
↓ 5.99%
Net Profit Margin
-49.74%
↑ 14.88%
FY19Y/Y Change
Revenue
302.3M
↑ 17.34%
Net Income
-124.8M
↓ 2.6%
Net Profit Margin
-41.29%
↑ 8.45%
FY20Y/Y Change
Revenue
391.0M
↑ 29.33%
Net Income
-229.7M
↑ 84.05%
Net Profit Margin
-58.76%
↓ 17.47%
FY21Y/Y Change
Revenue
625.5M
↑ 59.97%
Net Income
-471.7M
↑ 105.32%
Net Profit Margin
-75.42%
↓ 16.66%
FY22Y/Y Change
Revenue
820.2M
↑ 31.13%
Net Income
-547.8M
↑ 16.13%
Net Profit Margin
-66.79%
↑ 8.63%
FY23Y/Y Change
Revenue
1.1B
↑ 31.99%
Net Income
-434.8M
↓ 20.63%
Net Profit Margin
-40.16%
↑ 26.63%
Q4 FY22Q/Q Change
Revenue
217.3M
↑ 3.14%
Net Income
-142.6M
↑ 17.36%
Net Profit Margin
-65.63%
↓ 7.96%
Q1 FY23Q/Q Change
Revenue
241.8M
↑ 11.28%
Net Income
-136.9M
↓ 3.95%
Net Profit Margin
-56.64%
↑ 8.99%
Q2 FY23Q/Q Change
Revenue
261.4M
↑ 8.13%
Net Income
-110.8M
↓ 19.08%
Net Profit Margin
-42.39%
↑ 14.25%
Q3 FY23Q/Q Change
Revenue
268.3M
↑ 2.64%
Net Income
-109.0M
↓ 1.6%
Net Profit Margin
-40.64%
↑ 1.75%
Q4 FY23Q/Q Change
Revenue
311.1M
↑ 15.95%
Net Income
-78.0M
↓ 28.43%
Net Profit Margin
-25.08%
↑ 15.56%
Q1 FY24Q/Q Change
Revenue
367.7M
↑ 18.2%
Net Income
-67.6M
↓ 13.37%
Net Profit Margin
-18.38%
↑ 6.7%
FY18Y/Y Change
Total Assets
268.2M
↑ 50.0%
Total Liabilities
236.0M
↑ 24.78%
FY19Y/Y Change
Total Assets
582.7M
↑ 117.27%
Total Liabilities
303.9M
↑ 28.79%
FY20Y/Y Change
Total Assets
932.2M
↑ 59.98%
Total Liabilities
445.9M
↑ 46.71%
FY21Y/Y Change
Total Assets
1.2B
↑ 32.65%
Total Liabilities
583.2M
↑ 30.78%
FY22Y/Y Change
Total Assets
1.4B
↑ 12.78%
Total Liabilities
688.7M
↑ 18.1%
FY23Y/Y Change
Total Assets
1.5B
↑ 4.49%
Total Liabilities
691.8M
↑ 0.45%
Q4 FY22Q/Q Change
Total Assets
1.4B
↑ 38.19%
Total Liabilities
688.7M
↑ 6.37%
Q1 FY23Q/Q Change
Total Assets
1.3B
↓ 5.42%
Total Liabilities
668.3M
↓ 2.97%
Q2 FY23Q/Q Change
Total Assets
1.2B
↓ 5.38%
Total Liabilities
651.7M
↓ 2.48%
Q3 FY23Q/Q Change
Total Assets
1.4B
↑ 15.92%
Total Liabilities
661.9M
↑ 1.55%
Q4 FY23Q/Q Change
Total Assets
1.5B
↑ 0.73%
Total Liabilities
691.8M
↑ 4.52%
Q1 FY24Q/Q Change
Total Assets
1.5B
↑ 0.76%
Total Liabilities
674.1M
↓ 2.56%
FY18Y/Y Change
Operating Cash Flow
-70.6M
↓ 27.08%
Investing Cash Flow
-5.2M
↓ 137.44%
Financing Cash Flow
113.7M
↑ 41.5%
FY19Y/Y Change
Operating Cash Flow
-63.4M
↓ 10.11%
Investing Cash Flow
-266.4M
↑ 5060.88%
Financing Cash Flow
340.8M
↑ 199.65%
FY20Y/Y Change
Operating Cash Flow
-182.5M
↑ 187.67%
Investing Cash Flow
-331.5M
↑ 24.44%
Financing Cash Flow
500.8M
↑ 46.97%
FY21Y/Y Change
Operating Cash Flow
-335.2M
↑ 83.68%
Investing Cash Flow
-205.2M
↓ 38.09%
Financing Cash Flow
576.2M
↑ 15.04%
FY22Y/Y Change
Operating Cash Flow
-431.5M
↑ 28.72%
Investing Cash Flow
330.3M
↓ 260.99%
Financing Cash Flow
482.6M
↓ 16.24%
Q4 FY22Q/Q Change
Operating Cash Flow
-81.1M
↓ 20.66%
Investing Cash Flow
21.9M
↓ 67.09%
Financing Cash Flow
468.2M
↑ 33508.97%
Q1 FY23Q/Q Change
Operating Cash Flow
-80.9M
↓ 0.29%
Investing Cash Flow
15.7M
↓ 28.59%
Financing Cash Flow
2.3M
↓ 99.51%
Q2 FY23Q/Q Change
Operating Cash Flow
-78.4M
↓ 3.1%
Investing Cash Flow
47.0M
↑ 200.49%
Financing Cash Flow
9.3M
↑ 304.69%

Technicals Summary

Sell

Neutral

Buy

Natera Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Natera Inc
Natera Inc
-8.3%
56.1%
116.79%
-7.59%
277.91%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Natera Inc
Natera Inc
NA
NA
0.0
-2.44
-0.51
-0.17
NA
6.5
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Natera Inc
Natera Inc
Buy
$12.8B
277.91%
NA
-30.24%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Natera Inc

  • Increasing Revenue

    Revenue is up for the last 12 quarters, 142.02M → 367.74M (in $), with an average increase of 8.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -142.57M → -67.59M (in $), with an average increase of 16.9% per quarter

Institutional Holdings

  • Vanguard Group Inc

    8.99%

  • JPMorgan Chase & Co

    5.99%

  • Fred Alger Management, LLC

    5.33%

  • BlackRock Inc

    5.28%

  • Farallon Capital Management, L.L.C.

    3.20%

  • Ameriprise Financial Inc

    2.80%

Corporate Announcements

  • Natera Inc Earnings

    Natera Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the

Organization
Natera Inc
Employees
3282
CEO
Dr. Matthew Rabinowitz Ph.D.
Industry
Health Technology

Discover More

FAQs